Cornelius Engelmann 1, Oana Brosteanu 2, Hannelore Tenckhoff 1, Jana Babatz 3, Frank Lammert 4, Michael Manns 5, Ingolf Schiefke 6, Tony Bruns 7, Christian.

Slides:



Advertisements
Similar presentations
A Comparison of Early Versus Late Initiation of Renal Replacement Therapy in Critically III Patients with Acute Kidney Injury: A Systematic Review and.
Advertisements

Diuretic Strategies in Patients with Acute Decompensated Heart Failure Diuretic Optimization Strategies Evaluation (DOSE) trial.
Risё Stribling, MD Medical Director of Liver Transplant St Luke’s Medical Center Associate Professor of Surgery Baylor College of Medicine.
Teaching Liver cirrhosis with varices. Discussion  Approximately half of patients with cirrhosis have esophageal varices  One-third of all patients.
Hepatitis web study H EPATITIS C C URRICULUM Terry D. Box, MD Associate Professor of Medicine Division of Gastroenterology/Hepatology University of Utah.
Management of ascites in patients with cirrhosis Treviso 4 Giugno 2009 P. Angeli Dept. of Clinical and Experimental Medicine University of Padova.
Modified Megestrol The Clinical Trials by : Carolina R. Akib
CDI Education Cirrhosis 4/17/2017.
Liver pathology: CIRRHOSIS
Why GIVE a Liver Transplant to Patients with GAVE Syndrome
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Primary Aim To compare outcomes of participants with symptoms of stable angina or angina equivalent evaluated with an anatomic imaging strategy using CCTA.
HEPATO renal Syndrome Type I: Correct Diagnosis = Correct Management Stephen G. M. Wong BSc, BSc(Med), MD, MHSc, FRCPC Associate Professor of Medicine.
International Congress Highlights 2004 Clinical Update in GI disease Portal Hypertension P. Michielsen University of Antwerp
Bridging Oral Anticoagulation with Low Molecular Weight Heparin: Experience in 367 Patients with Renal Insufficiency Heyder Omran, Giso von der Recke,
Hepatorenal Syndrome Dr Allister J Grant Leicester Liver Unit
Creatinine (mg/dL) MonthsWeeks Therapeutic paracentesis Cefotaxime Type-2 HRSType-1 HRS Encephalopathy Jaundice CLINICAL TYPES.
LONG-TERM OUTCOME OF INTERFERON/RIBAVIRIN TREATMENT IN GERMAN REAL-LIFE SETTING: DURABLE SVR ASSOCIATED WITH LOW RATES OF LIVER-RELATED EVENTS S. Mauss.
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
Clinical Trial Designs An Overview. Identify: condition(s) of interest, intended population, planned treatment protocols Recruitment of volunteers: volunteers.
Cirrhosis 18 November 2009 Thomas C Sodeman MD Associate Professor of Medicine Chief, Division of Gastroenterology.
FT in prognostic of HBV FibroTest: predictive value in HBV.
High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention: Effects on Platelet Inhibition, Endothelial Function and Inflammation.
Incidence of hospitalisations in both groups Incidence of documented infections Abstract Problem statement: Patients on cancer chemotherapy are at substantial.
Kimberly Dunbar, PA-S2 Follow-up of Cardiovascular Risk Markers in Hypertensive Patients Treated with Irbesartan: Results of the i-SEARCH Plus Registry.
MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.
Acute On Chronic Liver Failure- Evolution of Concept 23 October 2015.
Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) Screening and randomisation Mette Krag Dept. of Intensive Care 4131 Copenhagen University.
Complications of Liver Cirrhosis
Acute Otitis Media: Lessons Learned Thomas Smith, M.D. Division of Anti-Infective Drug Products.
Copenhagen University Hospital Rigshospitalet, Denmark
Management of patients with cirrhosis and refractory ascites Treviso 4 Giugno 2009 P. Angeli Dept. of Clinical and Experimental Medicine University of.
Ascites and Spontaneous Bacterial Peritonitis Arthur Harris, MD Attending, Division of Gastroenterology Jacobi Medical Center/North Central Bronx Hospital.
A RandomizEd Trial of ENtERal Glutamine to MinimIZE Thermal Injury: A multicenter Pragmatic RCT (definitive study) Study Sponsor Dr. Daren Heyland Clinical.
1 NDA Clofarabine Cl-F-Ara-A Presented by Martin Cohen, M.D. at the December 01, 2004 meeting of the Oncologic Drugs Advisory Committee meeting.
R2 민준기 / 정재헌 교수님. Introduction Patients with resected high-risk locally advanced head and neck cancer –Expect favorable outcomes after concomitant radiochemotherapy(CCRT)
Journal Club Leona Isabella von Köckritz.
From: PLOS Neglected Tropical DiseaseJanuary 2014 Presented by Pavitra Charoensrisakkul and Peeraya Permkarnjaroen 3 rd year medical cadet Phramongkutklao.
Ascites 소화기내과 F1 김경엽.  Ascites: pathologic accumulation of fluid in the peritoneal cavity Causes of ascitesPercentage Cirrhosis81 % Cancer10 % Heart.
HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.
Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.
Dominique Valla, Richard Moreau, and Didier Lebrec
소화기내과 김경엽 Gastroenterology 2011;140:
INTRODUCTION. The annual incidence of liver transplant outcomes in South America has been unknown. So far direct correlations have been reported between.
Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.
Short-term effects of combination of satavaptan, a selective vasopressin V 2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without.
INTERNAL MEDICINE BENJAMIN YIP 4/13/16 Mini Lecture: Hepatorenal Syndrome.
RANDOMIZED PHASE II STUDY OF NABPACLITAXEL, IN RECURRENT ADVANCED OR METASTATIC CERVICAL CANCER MITO CER-NAB Enrica Mazzoni, MD Medical Oncology & Breast.
Total Occlusion Study of Canada (TOSCA-2) Trial
Nitroxoline does not result in microbiological eradication in geriatric patients with lower urinary tract infection: a prospective cohort study C. Forstner1,2*,,
Dr. Iram Shad PGT-Medicine MU-1, HFH,RWP
The Relationship between Postoperative Serum Albumin Level and Organ Dysfunction after Liver Transplantation. Results No differences were found between.
The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,
Fondazione IRCCS Istituto Nazionale Tumori
Copenhagen University Hospital Rigshospitalet, Denmark
The ADEMEX Trial Adequacy of PD in Mexico Reference
Jordi Bruix, Maria Reig, Morris Sherman  Gastroenterology 
Siân Cleaver1, Dr Nikki Pease2, Hilary Thomas2, Dr Audrey Yong2
Samantha King, Jill Jones MD, Russ Waitman PhD
Jordi Bruix, Maria Reig, Morris Sherman  Gastroenterology 
R Moreau, L Elkrief, C Bureau et al. Gastroenterology. Aug [Epub]
Effect of Prolonged Interferon Therapy on the Outcome of Hepatitis C Virus–Related Cirrhosis: A Randomized Trial  Laetitia Fartoux, Françoise Degos, Christian.
A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match–control study  M.-C. Tsai,
Vandana Khungar, Sammy Saab  Clinical Gastroenterology and Hepatology 
Andres Cardenas, Pere Ginès  Journal of Hepatology 
Internal medicine L-4 Liver cirrhosis & portal hypertension
MITO 26 PHASE II TRIAL ON TRABECTEDIN IN THE TREATMENT OF ADVANCED UTERINE AND OVARIAN CARCINOSARCOMA (CS)
Jordi Bruix, Maria Reig, Morris Sherman  Gastroenterology 
Presentation transcript:

Cornelius Engelmann 1, Oana Brosteanu 2, Hannelore Tenckhoff 1, Jana Babatz 3, Frank Lammert 4, Michael Manns 5, Ingolf Schiefke 6, Tony Bruns 7, Christian Trautwein 8, Stefan Zeuzem 9, Ulrich Treichel 10, Rajiv Jalan 11, Thomas Berg 1 1 University Hospital Leipzig, Division of Gastroenterology and Hepatology, Leipzig, Germany; 2 University Leipzig, Clinical trials centre, Leipzig, Germany; 3 University Hospital Dresden, Division of Gastroenterology, Dresden, Germany; 4University Hospital Homburg, Devision of Gastroenterology and Endocrinology, Homburg, Germany; 5 Hannover Medical School, Division of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany; 6 St. Georg Hospital, Division of Gastroenterology and Hepatology, Leipzig, Germany; 7 University Hospital Jena, Division of Gastroenterology, Hepatology and Infectiology, Jena, Germany; 8 University Hospital Aachen, Division of Gastroenterology, Metabolism and Intensive care, Aachen, Germany; 9 University Hospital Frankfurt, Division of Gastroenterology and Hepatology, Frankfurt, Germany; 10 General Hospital Hagenow; Division of Internal Medicine, Hagenow, Germany; 11 Royal Free Hospital, UCL Institute for Liver and Digestive Health, London, Great Britain BACKGROUND Ascites represents a complication of liver cirrhosis that becomes refractory to medical treatment in 5-10% of patients. The treatment of choice is repeated paracentesis or if applicable the implantation of a transjugular intrahepatic portosystemic shunt (TIPS). However, complications such as bleedings, hepatic encephalopathy and liver failure limit applicability of TIPS. The alfapump® system from Sequana Medical is a device implanted at subcutaneous level, which is able to move the ascitic fluid from the peritoneal cavity to the urinary bladder. Usually the device is implanted in patients with advanced stages of liver cirrhosis if TIPS is contraindicated. However, complications like renal insufficiency and infections largely result from this late disease stage. AIM The purpose of the Agua-Trial is to evaluate the efficacy of the alfapump in patients with cirrhosis presenting with recurrent or refractory ascites. Two patient populations are studied with different aims: 1.patients with indication to TIPS - the aim is to show that alfapump is non-inferior to TIPS in reducing the need for paracenteses. 2.patients with contraindication to TIPS - the aim is to show that alfapump is superior to repeated paracenteses, reducing the need for paracenteses. PERSPECTIVE REFERENCES Agua-Trial is the first large-sale clinical trial to evaluate the efficacy as well as the complications of alfapump in comparison with TIPS in patients with recurrent or refractory ascites qualifying for both treatments. Agua-Trial will provide important information about the clinical course of this condition and may have significant impact on treatment strategies in these patients. Arroyo V, Colmenero J. J Hepatol 2003; 38: S69–89. Ginès P et al;. J Hepatol 2010;53: Planas R et al. Clin Gastroenterol Hepatol 2006; 4: 1385–94. Arroyo V et al. Hepatology 1996; 23: 164–76. Pache I, Bilodeau M. Aliment Pharmacol Ther 2005;21:525–9. Ginès P et al. Gastroenterology 1988;94:1493–502. Lebrec D et al. J Hepatol 1996;25:135–44. Bellot J et al. J Hepatol 2013;58:922-7 Alfapump system versus transjugular intrahepatic portosystemic shunt and paracentesis in the treatment of ascites. A multicentre randomised controlled study (Agua-Trial) Contact Information Cornelius Engelmann Section of Hepatology, Clinic for Gastroenterology and Rheumatology, University Clinic Leipzig, Germany Liebigstraße 20, Leipzig Phone number: Fax number: Patients will be randomised using centralised randomisation stratified by site and frequency of paracentesis to ensure an approximate 1:1 ratio between both treatment groups overall and at all sites ENROLLMENT 1. Key Inclusion Criteria Males and non-pregnant females ≥ 18 years of age. Cirrhosis of the liver defined by histological and/or clinical, and/or radiological criteria Presenting recurrent and refractory ascites Capable of giving written informed consent and ability to operate the device Alcohol abstinence > 3 month No active chronic hepatitis C 2. Key Exclusion Criteria General contraindications indicating an advanced stage of liver cirrhosis: Bilirubin >5 mg/dl, INR > 1.5, Serum-Sodium <130 mmol/l ECOG >1 (Perfomance status) Renal failure defined as serum creatinine higher than or equal to 1,5 mg/dl recurring bacterial peritonitis and/or urinary infections hepatic or extra hepatic malignancy, unless adequately treated or in complete remission for ≥ 3 years. 3. Contraindication for TIPS-Implantation defining arm A (TIPS-Indication) and arm B (TIPS- Contraindication): left ventricular ejection fraction (EF) <40% pulmonary hypertension Hepatic encephalopathy Bilirubin > 3mg/dl Age >70 years Hepatocellular Carcinoma Primary Objective Is to evaluate the efficacy of the alfapump in comparison with TIPS and standard care for refractory/recurrent ascites Primary Endpoint: Average number of paracenteses per quarter (three month) documented over 4 quarters (1 year) Secondary Objective Is to evaluate the influence on life quality as well as safety of the alfapump in comparison with TIPS and standard medical care for refractory/recurrent ascites Secondary endpoints: Transplant-free survival Treatment related complications Cumulative Incidence of device failure Number of paracenteses within a quarter (3 month) with and without device failure Rate of therapeutic paracentesis and ascites volume that has been removed (starting four weeks after study inclusion) Rate of cirrhosis-related complications including infections Patients Quality of Life (chronic liver disease specific) Frequency and duration of hospital stays Nutrition: upper arm girth Amount (per patient) of albumin substitution OBJECTIVE/ENDPOINTS Two hundred sixty male and female patients ≥18 years with recurrent/refractory ascites with underlying cirrhosis at up to 20 European centres (Germany, Great Britain) TRIAL TREATMENTS After pump implantation prophylaxis against spontaneous bacterial peritonitis (SBP) with Ciprofloxacin 750mg/once weekly or norfloxacin 400mg/day. The alfapump System will be implanted using general anaesthesia or conscious sedation. The parameters of the device will be modified according to each patient’s individual requirements, setting the daily loss of ascitic fluid needed to maintain a stable body weight. TIPS will be implanted using standardized interventional radiological techniques. Albumin substitution is recommended according to the recommendation of the German as well as European guideline for the treatment of ascites: Renal insufficiency (according to AKIN; at least increase in serum creatinine ≥0.3 mg/dl or increase to ≥150% to 200% from baseline urine output 0.5 ml/kg/h for > 6 h) Large-volume paracentesis Spontaneous bacterial peritonitis RANDOMIZATIONDESIGN